Focused On-demand Library for Melanocortin-2 receptor accessory protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TCY5

UPID:

MRAP_HUMAN

Alternative names:

B27; Fat cell-specific low molecular weight protein; Fat tissue-specific low MW protein

Alternative UPACC:

Q8TCY5; Q5EBR3; Q8TDB7; Q8WXC1; Q8WXC2

Background:

The Melanocortin-2 Receptor Accessory Protein (MRAP), known by alternative names such as B27 and Fat tissue-specific low MW protein, plays a pivotal role in modulating melanocortin receptors (MC1R to MC5R). It enhances ligand sensitivity and cAMP generation, crucial for MC2R trafficking and ACTH response in adrenal cells, and may influence adipocyte intracellular pathways.

Therapeutic significance:

Linked to Glucocorticoid deficiency 2, a disorder marked by adrenal insufficiency and cortisol production failure, understanding MRAP's function could unveil new therapeutic avenues. Its involvement in ACTH receptor modulation and adrenal cortex activity highlights its potential in treating cortisol deficiency-related conditions.